Production capacity of vaccine to reach 610m a year: China

Novavax enters late-stage clinical trials

Agence France-Presse . Beijing | Published: 00:34, Sep 26,2020

 
 

China’s COVID-19 vaccine development programme is in a ‘leading position’ and Beijing expects annual production capacity to reach over 600 million doses by the end of the year, officials said Friday.

China has been bullish about the development of its coronavirus vaccine as scientists around the world race to halt the deadly  pathogen which has caused global chaos and killed almost a million people.

Health officials told reporters at a press conference Friday that China expects to be able to produce 610 million vaccine doses annually by the end of this year, and at least one billion doses annually next year.

Eleven Chinese vaccines have now entered clinical trials, with four in Phase Three trials that are ‘progressing smoothly’, said Wu Yuanbin from the Ministry of Science and Technology.

‘At present, China’s COVID-19 vaccine research and development work is overall in a leading position,’ said Wu.

‘We’ve seen that the vaccines’ safety is good and there have been no serious adverse reactions.’

Hundreds of thousands of essential workers at ports, hospitals and other high-risk areas have already been given an experimental vaccine since July, officials said, claiming that the programme had also gained the support of the World Health Organisation.

‘The safety of the emergency use vaccine has been fully authenticated, but its efficacy has not been fully certified,’ said Zheng Zhongwei, an official at the National Health Commission.

‘Up until now, there has not been one serious adverse reaction from all participants in the Covid emergency vaccine programme,’ Zheng added. He insisted the final vaccine would be ‘affordable for the general public.’

There are 59 vaccines currently under research in China in total, according to Wu.

Chinese president Xi Jinping has previously declared that Chinese vaccines would be made a ‘global public good’.

Two vaccines produced by China National Biotec Group, a subsidiary of Sinopharm, have been tested on over 35,000 people during Phase Three trials in the Middle East, Wu said.

Sinovac — another leading vaccine producer — has also been carrying out Phase Three trials in countries in South America and Southeast Asia, Wu added.

A vaccine jointly developed by CanSino Biologics and the Chinese military has been approved for Phase Three trials in countries in Europe and Asia.

Russia has boasted that it created the world’s first approved coronavirus vaccine, Sputnik V, although it is still undergoing clinical trials.

Meanwhile, US biotech firm Novavax said Thursday it was initiating its final Phase 3 clinical trial for its experimental COVID-19 vaccine.

The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.

‘With a high level of SARS-CoV-2 transmission observed and expected to continue in the UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373’s efficacy,’ said Gregory Glenn, the company’s president of research and development, using the technical name for the formulation.

It is the eleventh COVID-19 vaccine candidate to reach the Phase 3 stage globally.

The company has been awarded $1.6 billion by the US government to develop and fund the drug, which is administered by two intramuscular injections.

The Maryland-based company uses insect cells to grow synthesized pieces of the spike protein of the virus, which it hopes will evoke a robust human immune response.

It also uses an ‘adjuvant,’ a compound that boosts the production of neutralising antibodies.

The company says the drug, which is a liquid formulation, can be stored at two degrees celsius to eight degrees celsius, refrigerator temperature.

More about:

Want stories like this in your inbox?

Sign up to exclusive daily email

Advertisement

 

Advertisement

images